Skip Navigation


Rheumatology Advance Access originally published online on October 14, 2008
Rheumatology 2008 47(12):1838-1840; doi:10.1093/rheumatology/ken384
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/12/1838-a    most recent
ken384v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nagashima, T.
Right arrow Articles by Minota, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagashima, T.
Right arrow Articles by Minota, S.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B

T. Nagashima1 and S. Minota1

1Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan

Correspondence to: T. Nagashima, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Yakushiji 3311-1, Shimotsuke-shi, Tochigi 329-0498, Japan. E-mail: naga4ma@jichi.ac.jp

The first 10% of the full text of this article appears below.

SIR, Immunosuppressive therapy for patients with RA and HBV infection is a difficult problem clinically [1]. Tocilizumab is a humanized anti-IL-6 receptor antibody that has become a new treatment option for RA [2]. Here we report the first RA patient who was an HBV carrier and received tocilizumab.

A 60-yr-old Japanese woman had suffered from RA for 20 yrs, and had been followed at our Rheumatology Division since October 1993. RF and anti-cyclic citrullinated peptide antibody were positive, and her radiological grade was . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
W. DANIEL, V. DI MARTINO, and G. HERBEIN
Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. Where Are We?
J Rheumatol, June 1, 2009; 36(6): 1107 - 1108.
[Full Text] [PDF]